Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2005-01-01

[Enzyme replacement therapy in Fabry's disease].

L Alvarez, C del Pozo, M Trigueros, L Sánchez, M D Albero, R López-Menchero, E Ortega

Index: Nefrologia 25(3) , 322-7, (2005)

Full Text: HTML

Abstract

We report a 56-year-old man with history of chronic renal failure, who was diagnosed to have Fabry's disease after performing a percutaneous kidney biopsy. The diagnosis was confirmed by the deficient level of activity of alpha-galactosidase A and by the identification of the mutation. A enzime replacement therapy with alpha-galactosidase A was administered. After 18 months of treatment, a second kidney biopsy was performed showing renal deposits of globotriaosylceramide (we did not evaluate the percentage of histologic clearance of the deposits). Six months after the end of the therapy, a reduction in the impairment of renal function is observed, and the classic manifestations of the disease are absent.

Related Compounds

Related Articles:

Shiga toxin glycosphingolipid receptor expression and toxin susceptibility of human pancreatic ductal adenocarcinomas of differing origin and differentiation.

2012-08-01

[Biol. Chem. 393(8) , 785-99, (2012)]

High expression of lactotriaosylceramide, a differentiation-associated glycosphingolipid, in the bone marrow of acute myeloid leukemia patients.

2012-07-01

[Glycobiology 22(7) , 930-8, (2012)]

Binding interactions of Escherichia coli with globotetraosylceramide (globoside) using a surface plasmon resonance biosensor.

2004-09-01

[J. Microbiol. Methods 58(3) , 313-20, (2004)]

Parvovirus B19 does not bind to membrane-associated globoside in vitro.

2005-02-05

[Virology 332(1) , 189-98, (2005)]

Structural characterization and dynamics of globotetraosylceramide in vascular endothelial cells under TNF-alpha stimulation.

2010-02-01

[Glycoconj. J. 27(2) , 287-96, (2010)]

More Articles...